On Tuesday, Alzamend Neuro, Inc. ALZN introduced its plans to provoke a part 2 medical research of AL001 for sufferers with post-traumatic stress dysfunction (PTSD) within the fourth quarter of 2025.
The research follows Tesla Dynamic Coils BV’s completion of a head coil, a key part of the medical trial.
In collaboration with Massachusetts Common Hospital as its contract analysis group, Alzamend goals to discover the properties of AL001 and its results on lithium supply within the mind in comparison with marketed lithium salts.
Additionally Learn: EXCLUSIVE: Alzamend Neuro Reveals Full Information From Nonclinical Research Of Its Lead Alzheimer’s Drug Potential
The research might illuminate the trail ahead in sufferers with PTSD by demonstrating AL001’s focused effectiveness and decreased systemic unintended effects.
Earlier research in mice have proven that AL001 ensures higher mind absorption whereas sustaining decrease ranges of lithium within the blood, paving the best way for safer and extra environment friendly remedies.
The corporate says that though lithium doesn’t have an FDA-approved indication for PTSD, case experiences counsel that lithium therapy could also be helpful for treating PTSD sufferers.
Therapy with low doses (300–600 mg/day) of lithium carbonate has been reported to offer efficient therapy within the discount of inappropriate anger, irritability, anxiousness, and insomnia in these sufferers.
The medical commentary of temper swings past the conventional vary however milder than these related to bipolar dysfunction reportedly instructed the presence of a sub-threshold temper dysfunction in these PTSD sufferers.
It has additionally been proposed that therapy of trauma with lithium to forestall the event of PTSD could also be offered by pharmacological induction of gentle transient amnesia.
In March, Alzamend Neuro introduced its plans to provoke a part 2 medical research of AL001 for bipolar dysfunction, which is predicted to start within the third quarter of 2025.
Value Motion: ALZN inventory is up 2.99% at $0.73 throughout the premarket session on the final examine Tuesday.
Learn Subsequent:
Momentum2.01
Progress–
High quality–
Worth–
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
